Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) went up by 6.88% from its latest closing price compared to the recent 1-year high of $7.45. The company’s stock price has collected -7.35% of loss in the last five trading sessions.
Is It Worth Investing in Paratek Pharmaceuticals Inc. (NASDAQ :PRTK) Right Now?
Plus, the 36-month beta value for PRTK is at 1.39. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Paratek Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $21.00, which is $16.48 above the current price. PRTK currently public float of 45.44M and currently shorts hold a 12.25% ratio of that float. Today, the average trading volume of PRTK was 615.31K shares.
PRTK’s Market Performance
PRTK stocks went down by -7.35% for the week, with a monthly drop of -0.53% and a quarterly performance of -40.57%, while its annual performance rate touched -73.79%. The volatility ratio for the week stands at 7.25% while the volatility levels for the past 30 days are set at 10.03% for Paratek Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 1.66% for PRTK stocks with a simple moving average of -46.31% for the last 200 days.
Analysts’ Opinion of PRTK
Many brokerage firms have already submitted their reports for PRTK stocks, with WBB Securities repeating the rating for PRTK by listing it as a “Strong Buy.” The predicted price for PRTK in the upcoming period, according to WBB Securities is $11 based on the research report published on February 10th of the current year 2022.
WBB Securities, on the other hand, stated in their research note that they expect to see PRTK reach a price target of $10, previously predicting the price at $6. The rating they have provided for PRTK stocks is “Buy” according to the report published on April 23rd, 2021.
Jefferies gave a rating of “Buy” to PRTK, setting the target price at $15 in the report published on March 02nd of the previous year.
PRTK Trading at -4.87% from the 50-Day Moving Average
After a stumble in the market that brought PRTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.89% of loss for the given period.
Volatility was left at 10.03%, however, over the last 30 days, the volatility rate increased by 7.25%, as shares surge +2.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.27% lower at present.
During the last 5 trading sessions, PRTK rose by +0.26%, which changed the moving average for the period of 200-days by -63.58% in comparison to the 20-day moving average, which settled at $1.9892. In addition, Paratek Pharmaceuticals Inc. saw -57.91% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PRTK starting from BIGHAM MICHAEL, who sale 17,819 shares at the price of $4.27 back on Dec 15. After this action, BIGHAM MICHAEL now owns 890,782 shares of Paratek Pharmaceuticals Inc., valued at $76,087 using the latest closing price.
Brenner Randall B., the Chief Development & Regulatory of Paratek Pharmaceuticals Inc., sale 15,780 shares at $4.27 during a trade that took place back on Dec 15, which means that Brenner Randall B. is holding 253,530 shares at $67,381 based on the most recent closing price.
Stock Fundamentals for PRTK
Current profitability levels for the company are sitting at:
- -31.60 for the present operating margin
- +83.15 for the gross margin
The net margin for Paratek Pharmaceuticals Inc. stands at -45.39. Equity return is now at value 49.70, with -32.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.86.